⚠ Evidence warning: Clinical trials or other evidence do not support the claims that cat's claw helps clear Lyme disease, supports immunity during antibiotic courses, disrupts Borrelia biofilms and softens Herxheimer reactions. This page keeps it as a report of what people, websites or other media say.

Cat's Claw for Lyme Disease (Adjunctive)

Lyme Disease Adjunctive — scientific infographic poster

Cat's Claw is one of the most widely used herbal adjuncts in integrative Lyme disease protocols — appearing prominently in both the Cowden Condensed Support Program and Stephen Buhner's core herbal protocol — but the honest framing of the evidence is that no randomized controlled trial has demonstrated that Cat's Claw eradicates Borrelia burgdorferi in humans. What exists is laboratory (in-vitro) evidence (a 2020 Johns Hopkins screen in which Cat's Claw at 1% was active against non-growing, stationary-phase B. burgdorferi but needed high concentrations to stop growing bacteria; a 2010 report on a TOA-free whole-bark Cat's Claw extract), a mechanistic case put forward by practitioners (NF-kB modulation to reduce neuroinflammation, immune support during prolonged antibiotic courses, biofilm-disrupting proanthocyanidins, pleiotropic effects across the persister-form biology), and 25+ years of reported clinical use in integrative Lyme practice under the supervision of Lyme-literate physicians. For Lyme use specifically, the Cowden and Buhner protocols specify TOA-free or POA-standardized Cat's Claw. A TOA-free Uncaria tomentosa liquid extract is the form used in the Cowden protocol; the reason practitioners give is that the TOA chemotype's central nervous system-active alkaloids may aggravate Lyme neurological symptoms and antagonize the immune-modulating effect needed to support antibiotic clearance. In these protocols Cat's Claw is used as an immune-modulating adjunct alongside conventional antibiotic therapy, not as a stand-alone Lyme cure.


Table of Contents

  1. Honest Framing of the Lyme Evidence
  2. Why Borrelia burgdorferi Is So Hard to Eradicate
  3. Laboratory Screens of Cat's Claw Against Borrelia
  4. Datar et al. on Whole-Herb Preparations
  5. The Cowden Condensed Support Program (TOA-Free Cat's Claw Extract)
  6. The Buhner Core Herbal Protocol
  7. Why Lyme Protocols Specify TOA-Free Cat's Claw
  8. The Adjunctive Mechanistic Case (Biofilm, Immune, NF-kB)
  9. Cat's Claw Alongside Conventional Antibiotic Therapy
  10. Tick-Borne Coinfections (Babesia, Bartonella, Ehrlichia)
  11. Key Research Papers
  12. Connections
  13. Featured Videos

Honest Framing of the Lyme Evidence

The Lyme disease evidence space is contentious, with significant disagreement between the conservative mainstream view (represented by the Infectious Diseases Society of America guidelines) and the integrative / chronic-Lyme community (represented by ILADS, Lyme-literate physicians, and protocol developers like Cowden and Buhner). Cat's Claw sits squarely in the integrative side of that divide. Producing an honest discussion requires distinguishing what is solidly demonstrated from what is mechanistically plausible but not yet proven.

What is solidly demonstrated:

What is not solidly demonstrated:

A 2023 University of Maryland review of 18 herbs that people commonly use for lingering symptoms attributed to Lyme disease found laboratory (in-vitro) activity against B. burgdorferi for 7 of them — cat's claw, cryptolepis, Chinese skullcap, Japanese knotweed, sweet wormwood, thyme and oil of oregano — but “In vivo data and clinical trials are lacking.” The review notes that many of these herbs have drug interactions and additive effects that could raise the risk of bleeding, low blood pressure (hypotension) and low blood sugar (hypoglycemia) (Thompson 2023).

How integrative practice uses it: Cat's Claw is one component of integrative Lyme protocols, used under the supervision of a Lyme-literate physician alongside (not instead of) antibiotic therapy. The strength of the evidence is "mechanistically plausible, in-vitro suggestive, clinically experiential" rather than "proven by randomized trial." No study shows that Cat's Claw cures Lyme disease on its own.

Back to Table of Contents

Why Borrelia burgdorferi Is So Hard to Eradicate

To understand why integrative Lyme protocols are built the way they are, and why adjunctive herbs like Cat's Claw have become standard in those protocols, it helps to understand what makes Borrelia burgdorferi a uniquely difficult bacterium to eliminate.

Morphological plasticity. B. burgdorferi exists in at least three distinct morphological forms:

Immune evasion. B. burgdorferi alters surface antigen expression (the variable major protein-like sequence, VlsE, undergoes rapid recombination to generate antigenic variation), down-regulates surface antigens when targeted by antibodies, can sequester intracellularly in fibroblasts and macrophages, and produces immunosuppressive factors at the local infection site.

Tissue tropism. B. burgdorferi preferentially localizes to collagenous and connective tissues that are relatively avascular — the synovium of joints, the connective tissue of the heart valves, the meninges and dural sleeves of nerve roots, and tendons and ligaments. These tissues have poor antibiotic penetration compared to highly vascularized organs.

The clinical consequence. Standard 14-21 day antibiotic courses, while curative for the majority of early-localized Lyme disease, leave a meaningful minority of patients with persistent symptoms attributed to either residual infection, post-infectious inflammation, or both. This is the population that fuels the chronic-Lyme / post-treatment Lyme disease syndrome (PTLDS) controversy and the integrative-protocol approach. Any therapy that combines (a) activity against round-body and biofilm forms, (b) immune support during prolonged antibiotic courses, and (c) anti-inflammatory effects on the persistent neuroinflammation has an immediately appealing mechanistic profile — which is exactly the profile Cat's Claw offers.

Back to Table of Contents

Laboratory Screens of Cat's Claw Against Borrelia

The 2015 paper by Theophilus, Victoria, Socarras, Filush, Gupta, Luecke and Sapi of the University of New Haven, published in the European Journal of Microbiology and Immunology, is sometimes cited for Cat's Claw, but it tested only whole-leaf Stevia rebaudiana extract against Borrelia burgdorferi spirochetes, persisters and biofilms, compared with the antibiotics doxycycline, cefoperazone and daptomycin. It did not test Cat's Claw. The laboratory screen that did test Cat's Claw is a 2020 study from the Johns Hopkins Bloomberg School of Public Health by Feng, Leone, Schweig and Zhang, published in Frontiers in Medicine.

Design. Twelve commonly used botanical medicines and three other natural antimicrobial agents were tested against B. burgdorferi B31 strain (the standard laboratory reference strain), both as actively growing cultures and as non-growing stationary-phase cultures, and compared with the antibiotics doxycycline and cefuroxime. The Cat's Claw tested was a water extract of wild-harvested bark. Bacterial viability was assessed by SYBR Green I / propidium iodide dual staining (live/dead microscopy) and by 21-day subculture.

Findings relevant to Cat's Claw.

Important interpretive caveats.

The Feng 2020 screen is laboratory (test-tube) evidence of Cat's Claw activity against non-growing B. burgdorferi; it is not clinical efficacy data.

Back to Table of Contents

Datar et al. on Whole-Herb Preparations

A 2010 report by Datar, Kaur, Patel, Luecke and Sapi, published in the Townsend Letter (a practitioner journal not indexed in PubMed), examined a TOA-free whole-bark Cat's Claw liquid extract used in the Cowden protocol, together with an Otoba parvifolia extract from the same protocol, against the different morphological forms of Borrelia burgdorferi. A 2018 laboratory study summarises these two extracts as having been “demonstrated to have anti-inflammatory and antimicrobial properties, e.g., against different morphological forms of Borrelia burgdorferi” (Weiss 2018). Practitioners also describe whole-herb preparations as more active than purified single-compound fractions — an observation consistent with the hypothesis that Cat's Claw's anti-Borrelia activity requires the combined action of multiple compound classes.

The whole-herb-vs-isolated-compound observation is important because it suggests that pharmaceutical attempts to isolate a single "active ingredient" from Cat's Claw may miss the point. The pentacyclic oxindole alkaloids contribute the immune-modulating activity, the quinovic acid glycosides contribute direct antimicrobial activity, the proanthocyanidins contribute biofilm-disrupting activity and direct bacterial membrane effects, and the triterpenes contribute additional anti-inflammatory and immune support. A whole-bark POA-standardized extract delivers all four fractions in their native ratio.

Back to Table of Contents

The Cowden Condensed Support Program (TOA-Free Cat's Claw Extract)

The Cowden Condensed Support Program is one of the two best-known integrative protocols for chronic Lyme disease (the other being Buhner's). It was developed by W. Lee Cowden, MD, a Texas integrative cardiologist who became prominent in the Lyme treatment community in the early 2000s. The protocol uses primarily microbial-rich liquid herbal extracts under a structured rotation schedule.

Within the Cowden protocol, Cat's Claw appears specifically as a TOA-free Uncaria tomentosa liquid extract — a proprietary bark preparation described as TOA-free (verified by laboratory analysis to contain pentacyclic alkaloids only, with tetracyclic alkaloids below detection limit). This preparation has been used in the Cowden protocol since the late 1990s and is one of the most widely used Cat's Claw preparations in chronic Lyme practice.

Typical dosing of this extract in the Cowden protocol involves slow titration upward over weeks — starting at 1–2 drops twice daily and gradually increasing to 30 drops twice daily over several months. The slow titration is intended to minimize Herxheimer-like reactions (the inflammatory response to bacterial die-off that can transiently worsen symptoms) and to allow assessment of individual tolerance.

The protocol typically pairs this extract with several other immune-modulating and antimicrobial herbal extracts in rotation, including extracts of Otoba parvifolia and Campsiandra angustifolia, and others. The rotation is intended to address the multiple morphological forms of Borrelia and to reduce the likelihood of bacterial adaptation to any single antimicrobial pressure.

The clinical evidence base for the full Cowden protocol is observational and uncontrolled — there are no randomized trials of the protocol vs standard antibiotic therapy alone. Practitioners using the protocol report clinical experience suggesting benefit, particularly in patients with established post-treatment Lyme disease syndrome who have not responded fully to conventional therapy. Its practitioners describe it as one approach among several in the Lyme-literate integrative community; it is not a proven cure.

Back to Table of Contents

The Buhner Core Herbal Protocol

Stephen Harrod Buhner (1952–2022) was an herbalist and author whose books "Healing Lyme" (first edition 2005, second edition 2015) and "Healing Lyme Disease Coinfections" (2013) became foundational reference works in the integrative-Lyme community. Buhner's protocols are different in flavor from Cowden's — more dry-herb and tincture based, drawing on a broader range of traditional herbal pharmacopeias, and structured around the specific co-infections present rather than around a single rotation schedule.

Cat's Claw appears in Buhner's protocol as a core immune-modulating herb alongside astragalus, eleuthero, and other adaptogens. Buhner specifically calls out the pentacyclic-vs-tetracyclic chemotype issue and the requirement for POA-standardized preparations. The Buhner dosing is typically dry-bark tincture (1:5 in 60% ethanol) at 1–2 mL three times daily, with adjustment based on individual response.

The Buhner core protocol for Lyme disease itself emphasizes Polygonum cuspidatum (Japanese knotweed) as the primary anti-spirochete herb (the resveratrol and emodin content drives the anti-Borrelia activity in his system), with Andrographis paniculata as the secondary anti-spirochete herb, and Cat's Claw as the immune-modulating support layer. For neurological Lyme specifically, Buhner adds additional herbs targeting neuroinflammation.

Like the Cowden protocol, the Buhner protocols are observational and unblinded in their evidence base — no controlled trials of the full protocol have been done. Buhner himself was explicit that his protocols were a synthesis of available evidence and clinical experience, not a substitute for individual case evaluation by a knowledgeable practitioner.

Back to Table of Contents

Why Lyme Protocols Specify TOA-Free Cat's Claw

The chemotype-quality issue discussed throughout this Benefits hub is particularly important in the Lyme disease context, for two interlocking reasons.

First, the immune-modulating effect that supports the rationale for using Cat's Claw in Lyme is specifically the POA-driven effect. The Cowden and Buhner protocols specify POA-standardized or TOA-free products. The mechanistic case for Cat's Claw in Lyme — immune support during prolonged antibiotic courses, NF-kB modulation of neuroinflammation, persister-form activity — is built entirely on POA pharmacology. A TOA-contaminated product would not be expected to deliver these effects, and as discussed elsewhere, the TOA actively antagonizes the POA immune modulation.

Second, the tetracyclic alkaloids have central nervous system-active effects that may be specifically problematic in Lyme neuroborreliosis. Rhynchophylline and isorhynchophylline are central nervous system active — they have effects on glutamate signaling, calcium channels, and dopamine signaling. In a patient with Lyme-associated neuroinflammation, neurocognitive symptoms (brain fog, mood disturbance, peripheral neuropathy, autonomic dysfunction), and disrupted sleep, additional central nervous system-active alkaloids of uncertain effect are, in the protocols' reasoning, unwanted. TOA-free certification means these alkaloids are below the detection limit.

For Lyme use specifically, the products these protocols use are TOA-free Cat's Claw liquid extracts (the form used in the Cowden protocol) and POA-standardized capsules with documented TOA-free testing. For unlabelled "Cat's Claw" supplements sold in chain pharmacies and discount retailers, the chemotype is unknown and the activity is correspondingly unpredictable; the protocols do not use them.

Back to Table of Contents

The Adjunctive Mechanistic Case (Biofilm, Immune, NF-kB)

Practitioners place Cat's Claw in Lyme disease as an adjunctive immune-modulating layer alongside conventional antibiotic therapy. Their mechanistic rationale has three legs.

None of these three legs is proof of clinical efficacy in Lyme disease. Together, they form the mechanistic basis for the integrative-protocol use, and they explain why Cat's Claw has remained a fixture in Lyme practice for two decades despite the absence of randomized controlled trial evidence.

Back to Table of Contents

Cat's Claw Alongside Conventional Antibiotic Therapy

In integrative practice Cat's Claw is used in Lyme disease as an adjunct to, not a substitute for, conventional antibiotic therapy. By stage:

For more on Lyme disease itself, see the Lyme Disease overview and the deep-dive sub-articles covering tick bite first aid and prophylaxis, antibiotic treatment protocols, and the erythema migrans rash guide.

Back to Table of Contents

Tick-Borne Coinfections (Babesia, Bartonella, Ehrlichia)

Patients with Lyme disease frequently harbor co-infections with other tick-borne pathogens transmitted by Ixodes ticks (the same vector as B. burgdorferi). The main co-infections are:

In integrative practice, Cat's Claw is used as a general immune-modulating and anti-inflammatory adjunct in the broader tick-borne illness landscape. It is not the primary therapy for any specific co-infection: confirmed or suspected co-infections are treated with antibiotics targeted at the specific pathogens, with Cat's Claw as a supportive layer in integrative protocols.

Back to Table of Contents

Key Research Papers

  1. Theophilus PA, Victoria MJ, Socarras KM, et al. (2015). Effectiveness of Stevia rebaudiana whole leaf extract against the various morphological forms of Borrelia burgdorferi in vitro. (Tested Stevia only; no Cat's Claw.) European Journal of Microbiology and Immunology 5(4): 268–280. — PubMed PMID: 26716015
  2. Datar A, Kaur N, Patel S, Luecke DF, Sapi E (2010). In vitro effectiveness of samento and banderol herbal extracts on the different morphological forms of Borrelia burgdorferi. Townsend Letter. (Not indexed in PubMed; no PMID.)
  3. Feng J, Leone J, Schweig S, Zhang Y (2020). Evaluation of natural and botanical medicines for activity against growing and non-growing forms of B. burgdorferi. Frontiers in Medicine 7: 6. — PubMed PMID: 32154254
  4. Thompson A, Hynicka LM, Shere-Wolfe KD (2023). A comprehensive review of herbal supplements used for persistent symptoms attributed to Lyme disease. Integrative Medicine (Encinitas) 22(1): 30–38. — PubMed PMID: 37101730
  5. Weiss J (2018). Herb-drug interaction potential of anti-Borreliae effective extracts from Uncaria tomentosa (Samento) and Otoba parvifolia (Banderol) assessed in vitro. Molecules 24(1): 137. — PubMed PMID: 30602711
  6. Snow AD, Castillo GM, Nguyen BP, et al. (2019). The Amazon rain forest plant Uncaria tomentosa (cat's claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles. Scientific Reports 9(1): 561. — PubMed PMID: 30728442
  7. Goc A, Niedzwiecki A, Rath M (2015). In vitro evaluation of antibacterial activity of phytochemicals and micronutrients against Borrelia burgdorferi and Borrelia garinii. Journal of Applied Microbiology 119(6): 1561–1572. — PubMed PMID: 26457476
  8. Sapi E, Bastian SL, Mpoy CM, et al. (2012). Characterization of biofilm formation by Borrelia burgdorferi in vitro. PLOS ONE 7(10): e48277. — PubMed PMID: 23110225
  9. Feng J, Zhang S, Shi W, et al. (2017). Selective essential oils from spice or culinary herbs have high activity against stationary phase and biofilm Borrelia burgdorferi. Frontiers in Medicine 4: 169. — PubMed PMID: 29075628
  10. Cabello FC, Embers ME, Newman SA, Godfrey HP (2022). Borreliella burgdorferi antimicrobial-tolerant persistence in Lyme disease and post-treatment Lyme disease syndromes. mBio 13(3): e0344021. — PubMed PMID: 35467428
  11. Sandoval-Chacon M, Thompson JH, Zhang XJ, et al. (1998). Antiinflammatory actions of cat's claw: the role of NF-kappaB. Alimentary Pharmacology & Therapeutics 12(12): 1279–1289. — PubMed PMID: 9882039
  12. Sheng Y, Bryngelsson C, Pero RW (2000). Enhanced DNA repair, immune function and reduced toxicity of C-MED-100, a novel aqueous extract from Uncaria tomentosa. Journal of Ethnopharmacology 69(2): 115–126. — PubMed PMID: 10687868
  13. Keplinger K, Laus G, Wurm M, Dierich MP, Teppner H (1999). Uncaria tomentosa (Willd.) DC. — ethnomedicinal use and new pharmacological, toxicological and botanical results (POA/TOA antagonism). Journal of Ethnopharmacology 64(1): 23–34. — PubMed PMID: 10075119
  14. Lantos PM, Rumbaugh J, Bockenstedt LK, et al. (2021). Clinical practice guidelines by IDSA/AAN/ACR: 2020 guidelines for the prevention, diagnosis, and treatment of Lyme disease. Clinical Infectious Diseases 72(1): 1–8. — PubMed PMID: 33483734
  15. Cameron DJ, Johnson LB, Maloney EL (2014). Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Review of Anti-infective Therapy 12(9): 1103–1135. (ILADS guideline) — PubMed PMID: 25077519
  16. Aucott JN, Crowder LA, Kortte KB (2013). Development of a foundation for a case definition of post-treatment Lyme disease syndrome. International Journal of Infectious Diseases 17(6): e443–e449. — PubMed PMID: 23462300

PubMed Topic Searches

  1. PubMed: Uncaria tomentosa Lyme disease borrelia
  2. PubMed: Borrelia persister forms and biofilm
  3. PubMed: Cowden protocol Lyme
  4. PubMed: Buhner herbal protocol Lyme
  5. PubMed: Post-treatment Lyme disease syndrome treatment

Back to Table of Contents

Connections

Back to Table of Contents